United Kingdom Bronchopulmonary Dysplasia Market Insight
Published: 17 June 2026 | Report Format: Electronic (PDF)
The United Kingdom Bronchopulmonary Dysplasia (BPD) Market is projected to grow at a CAGR of around 7.1%, driven by increasing prevalence of premature births and advancements in neonatal intensive care technologies.
United Kingdom Bronchopulmonary Dysplasia Market Forecasts to 2035
- The United Kingdom Bronchopulmonary Dysplasia Market size was estimated at approximately USD 0.17 Billion in 2025.
- The market is expected to grow at a CAGR of around 7.1% from 2025 to 2035.
- The United Kingdom Bronchopulmonary Dysplasia Market is projected to reach approximately USD 0.34 Billion by 2035.
Notable Insights for the United Kingdom Bronchopulmonary Dysplasia Market
- Segmentation based on treatment type indicates Respiratory Support Therapies account for approximately 47% market share in 2025, driven by increasing utilization of ventilators, CPAP systems, and oxygen therapy in neonatal intensive care units.
- Segmentation based on end user shows Hospitals & Neonatal Intensive Care Units (NICUs) holding nearly 71% market share in 2025, supported by specialized care requirements for premature infants with chronic lung disease.
- The United Kingdom Bronchopulmonary Dysplasia Market is led by major companies including Chiesi Farmaceutici S.p.A., Medtronic plc, Fisher & Paykel Healthcare, Drägerwerk AG & Co. KGaA, and GE HealthCare Technologies Inc., collectively accounting for approximately 52% market share in 2025.
- Growing investments in neonatal healthcare infrastructure, advanced respiratory support technologies, and early intervention programs have increased adoption of BPD management solutions by nearly 29% over the past five years.
Download the eBook (ToC)
Why Buy This Report
- Provides in-depth analysis of bronchopulmonary dysplasia treatment demand across hospitals, neonatal intensive care units, specialty pediatric centers, and research institutions.
- Covers detailed insights into respiratory support systems, pharmacological therapies, oxygen management solutions, and neonatal care advancements.
- Helps stakeholders evaluate competitive positioning, growth opportunities, and investment potential within the United Kingdom neonatal respiratory care ecosystem.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Bronchopulmonary Dysplasia Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Bronchopulmonary Dysplasia Market
- Chiesi Farmaceutici S.p.A.
- Medtronic plc
- Fisher & Paykel Healthcare Corporation Limited
- Drägerwerk AG & Co. KGaA
- GE HealthCare Technologies Inc.
- Vapotherm Inc.
- Vyaire Medical Inc.
- Teleflex Incorporated
- Inspiration Healthcare Group plc
- Philips Healthcare
Recent Developments:
- In May 2025, Fisher & Paykel Healthcare introduced advanced neonatal respiratory support technologies designed to optimize oxygen delivery and reduce respiratory complications in NICU settings.
- In February 2025, Intersurgical introduced enhanced single-use breathing circuits featuring improved infection control capabilities and optimized airflow performance for anesthesia and ventilation applications.
Market Segmentation:
United Kingdom Bronchopulmonary Dysplasia Market, By Treatment Type
- Respiratory Support Therapies
- Pharmacological Treatments
- Oxygen Therapy
- Nutritional Support
- Combination Therapies
United Kingdom Bronchopulmonary Dysplasia Market, By Disease Severity
- Mild BPD
- Moderate BPD
- Severe BPD
United Kingdom Bronchopulmonary Dysplasia Market, By End User
- Hospitals
- Neonatal Intensive Care Units (NICUs)
- Specialty Pediatric Clinics
- Academic & Research Institutes
- Home Healthcare Settings
Expert Views:
The United Kingdom Bronchopulmonary Dysplasia Market is expected to witness steady growth through 2035, supported by rising survival rates of premature infants, increasing prevalence of neonatal respiratory disorders, and expanding investments in neonatal healthcare infrastructure. Continuous innovation in respiratory support technologies, neonatal ventilation systems, targeted pharmacological therapies, and personalized neonatal care approaches is anticipated to improve clinical outcomes and strengthen long-term market growth across the healthcare sector.
Author: Komal and Radhika By Decisions Advisors and Consulting